Semaglutide 2.4mg for low responders after bariatric surgery
Key facts
- Where
- Beverwijk, Heerlen és Nieuwegein, HollandiaSee the 3 sites
- Phase
- 4. fázis
Where in Hollandia
- Rode Kruis Ziekenhuis B.V.Beverwijk, HollandiaTaking people
- Zuyderland Medisch Centrum StichtingHeerlen, HollandiaTaking people
- Sint Antonius Ziekenhuis StichtingNieuwegein, HollandiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Stichting Zuyderland Medisch Centrum
- Trial code
- EU 2022-502164-20-01
- Record updated
- 2025. március 6.
- Original description
To study the weight change from 3 to 18 months after surgery (% total weight loss, TWL) in low responders after bariatric surgery who are treated with Semaglutide 2.4 mg and a lifestyle intervention and compare change in weight to patients receiving placebo and a lifestyle intervention.Read full original descriptionShow less
To study the weight change from 3 to 18 months after surgery (% total weight loss, TWL) in low responders after bariatric surgery who are treated with Semaglutide 2.4 mg and a lifestyle intervention and compare change in weight to patients receiving placebo and a lifestyle intervention.
Inclusion: Patient is ≥18 and <75 years old; BMI before surgery was ≥ 35.0 kg/m2; Patient is treated with group consultation at the Dutch Obesity Clinic (DOC); Patient has undergone a primary (banded) RYGB or (banded) sleeve gastrectomy (SG); Patient is in the lowest %TWL quartile, 3 months after surgery and will be enrolled in the plus module.
Exclusion: Type 1 or type 2 diabetes; Liver failure (all); Congestive heart failure or angina pectoris NYHA class III and IV; Malignancy in history; Inflammatory Bowel Disease; Thyroid malignancy in history; Decreased renal function (creatinine clearance < 30 ml/min); Use of warfarin or other coumarin derivates; Pancreatitis (in history); Pregnancy / breast-feeding.